This article is more than 5 years old. Information may no longer be current.
Ixekizumab found effective for patients with psoriatic arthritis
Click Here to Manage Email Alerts
Patients treated with ixekizumab every 2 weeks or every 4 weeks had improved signs and symptoms compared with placebo, according to a recently published analysis.
“In agreement with other clinical trials investigating biologics targeting interleukin-17A signaling, these data further verify the role of interleukin-17A in the promotion of the pathogenesis of psoriatic arthritis,” Peter Nash, MD, from the University of Queensland in Australia, and colleagues wrote.
Researchers performed a randomized, controlled phase 3 trial of 363 patients with psoriatic arthritis and who had an inadequate response or were intolerant to tumor necrosis factor inhibitors.
After 24 weeks, investigators found a higher ACR20 response percentage in patients who took ixekizumab every 4 weeks (53%), as well as in patients who took ixekizumab every 2 weeks (48%) vs. patients who took placebo (33.8%). Serious adverse events were found in 3% of the 4-week group, in 7% of the 2-week group and in 3% of the placebo group; and there were no deaths in any of the groups. In addition, infections occurred in 39% of the 4-week group, in 38% of the 2-week group and in 30% of the placebo group. There were three serious infections and these all occurred in the 2-week group. – by Will A. Offit
Disclosures: Nash reports he received grants, personal fees and non-financial support from Eli Lilly, Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Hospira, MSD, Pfizer, Janssen, UCB, Novartis, Roche and Sanofi. Please see the full study for a list of all other relevant disclosures.
Click Here to Manage Email Alerts